Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCN4ZD)

Drug Name

AA-184 Drug Info

Synonyms

BMP agonist (acute kidney injury), Thrasos Therapeutics

Indication

Disease Entry	ICD 11	Status	REF
Kidney injury	NB92.0	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Bone morphogenetic protein receptor (BMPR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID23639540C13d	DMSTQGH	Discovery agent	N.A.	Investigative	[2]
PMID23639540C13a	DMLXOAQ	Discovery agent	N.A.	Investigative	[2]
PMID23639540C13r	DMHBZ0N	Discovery agent	N.A.	Investigative	[2]
LDN-214117	DM57Z8J	Discovery agent	N.A.	Investigative	[3]
ML347	DMR8N36	Discovery agent	N.A.	Investigative	[2]
AA-204	DMBGTX9	Kidney disease	GC2Z	Investigative	[1]
AA-123	DMW73A8	Prostate cancer	2C82.0	Investigative	[1]
AA-166	DM2BMAZ	Articular cartilage disorder	FA34.Y	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bone morphogenetic protein receptor (BMPR2)	TTGKF90	BMPR2_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794).
2	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
3	Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15.